Skip to search formSkip to main contentSkip to account menu

SDZ HTF 919

Known as: HTF 919, SDZ HTF-919 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tegaserod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Tegaserod Pharmacokinetics Are Similar in Patients with Severe Renal Insufficiency and in Healthy Subjects
Tegaserod (HTF 919), a selective 5‐HT4 receptor partial agonist with promotile activity throughout the gastrointestinal tract, is… 
2001
2001
The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young
Tegaserod (HTF 919) is a selective 5‐HT4 receptor partial agonist in development for the treatment of irritable bowel syndrome. 
2001
2001
The Effects of Tegaserod (HTF 919) on the Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects
Tegaserod (HTF 919) is a highly specific 5‐HT4 receptor partial agonist that exhibits promotile activity throughout the… 
2001
2001
高温加熱装置II型 (HTF-II-6) 開発に学ぶ技術ノウハウならびに提言
2000
2000
Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats
2000
2000
Tegaseroid (HTF 919), a partial 5-HT4 receptor agonist, accelerates gastrointestinal (GI) transit
2000
2000
Effects of tegaserod (HTF 919) on gastrointestinal motility and transit in awake rats
2000
2000
Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects
1997
1997
Clinical pharmacodynamics of SDZ HTF 919, a new 5‐HT4 receptor agonist, in a model of slow colonic transit
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)